Current status of non-viral gene therapy for CNS disorders
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Viral and non-viral vectors have been used as methods of delivery in gene therapy for many CNS diseases. Currently, viral vectors such as adeno-associated viruses (AAV), retroviruses, lentiviruses, adenoviruses and herpes simplex viruses (HHV) are being used as successful vectors in gene therapy at clinical trial levels. However, many disadvantages have risen from their usage. Non-viral vectors like cationic polymers, cationic lipids, engineered polymers, nanoparticles, and naked DNA offer a much safer option and can therefore be explored for therapeutic purposes. AREAS COVERED: This review discusses different types of viral and non-viral vectors for gene therapy and explores clinical trials for CNS diseases that have used these types of vectors for gene delivery. Highlights include non-viral gene delivery and its challenges, possible strategies to improve transfection, regulatory issues concerning vector usage, and future prospects for clinical applications. EXPERT OPINION: Transfection efficiency of cationic lipids and polymers can be improved through manipulation of molecules used. Efficacy of cationic lipids is dependent on cationic charge, saturation levels, and stability of linkers. Factors determining efficacy of cationic polymers are total charge density, molecular weights, and complexity of molecule. All of the above mentioned parameters must be taken care for efficient gene delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Design and development of polymers for gene delivery
Pack, D. W., Hoffman, A. S., Pun, S., & Stayton, P. S. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1775 · Cited by 2,568
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Xia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J. I., & Nel, A. E. (2009) · ACS Nano · doi:10.1021/nn900918w · Cited by 933
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Nonviral Gene Delivery: Principle, Limitations, and Recent Progress
Al-Dosari, M. S., & Gao, X. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9143-y · Cited by 706
The potential of magneto-electric nanocarriers for drug delivery
Kaushik, A., Jayant, R. D., Sagar, V., & Nair, M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.933803 · Cited by 113
Self-citation
Cited by
Caspase‐3: Structure, function, and biotechnological aspects
Asadi, M., Taghizadeh, S., Kaviani, E., Vakili, O., Taheri‐Anganeh, M., Tahamtan, M., & Savardashtaki, A. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2233 · Cited by 530
Recent advances in the development of gene delivery systems.
Sung, Y., & Kim, S. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0156-z · Cited by 458
New Advances in General Biomedical Applications of PAMAM Dendrimers
Araújo, R. V. D., Santos, S. D. S., Igne Ferreira, E., & Giarolla, J. (2018) · Molecules · doi:10.3390/molecules23112849 · Cited by 265
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
AL Qtaish, N., Gallego, I., Villate-Beitia, I., Sainz-Ramos, M., López-Méndez, T. B., Grijalvo, S., Eritja, R., Soto-Sánchez, C., Martínez-Navarrete, G., Fernández, E., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030198 · Cited by 57
“In this sense, the use of cell-type specific promoters, inducible promoters, or the rapamycin regulation system offer a reasonable option to confine gene expression only in specific cell types, which avoids off-target effects in other cells [153].”
Background
Metadata
- Authors
- Jayant, R. D., Sosa, D., Kaushik, A., Atluri, V., Vashist, A., Tomitaka, A., & Nair, M.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2016-06-01
- Volume
- 13
- Issue
- 10
- Pages
- 1433-1445
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2385719444
- Cited by
- 91
- References
- 8
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current status of non-viral gene therapy for CNS disorders. https://app.cochat.ai/papers/10.1080/17425247.2016.1188802
- The paper
- Jayant, R. D., Sosa, D., Kaushik, A., Atluri, V., Vashist, A., Tomitaka, A., & Nair, M. (2016). Current status of non-viral gene therapy for CNS disorders. Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2016.1188802
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.